Rentschler Biopharma

Rentschler Biopharma is a private, family-owned biopharmaceutical contract development and manufacturing organization focused on process development and cGMP manufacturing for client biologics programs. The company provides end-to-end services spanning analytical development, process development, formulation development, regulatory support, client program management, and clinical-to-commercial manufacturing. Its core focus is complex biopharmaceuticals, particularly mammalian-expression biologics and protein therapeutics, with manufacturing operations in Laupheim, Germany and Milford, Massachusetts. Rentschler previously built a UK advanced therapies capability, but in January 2025 announced a strategic withdrawal from cell and gene therapy and the closure of its Stevenage operations in order to increase focus on biologics. The company serves global biopharma customers and highlights contributions to multiple FDA-approved biopharmaceutical products.